BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It4.6.2026 14:33:00 CEST | Press release
Peer reviewed life cycle assessment published in the Journal of Dentistry (ISO 14040/14044-compliant) finds most impact comes from clinical care pathways, making prevention at home the biggest lever to improving outcomes for patients and the environment. Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601115251/en/ Oral-B iO9 Black The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the first time quantifies the environmental burden associated with the presence of periodontal disease, its progression and the associated
Corpay Cross-Border Named the Official FX Supplier of Vålerenga Fotball AS4.6.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Vålerenga Fotball AS to become their Official Foreign Exchange (FX) Supplier. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Vålerenga Fotball AS’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Vålerenga Fotball AS,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within professional football, while giving us a strong platform to expand our brand and business in Norw
CloudInteract and Red Kite Launch Joint Delivery Partnership for Agentic AI Voice on Amazon Connect and Pega4.6.2026 14:19:00 CEST | Press release
This expert partnership takes agentic voice deployments for customers from quarters to weeks; a demonstrator can be seen at PegaWorld 2026 CloudInteract, the Amazon Connect and agentic AI specialist, and Red Kite, the Pega delivery partner, today announced a joint delivery partnership to bring autonomous AI voice agents to enterprises using the Pega and Amazon Connect platforms. The partnership debuts a working solution on Amazon Connect, Amazon Bedrock, that can be seen at PegaWorld® in Las Vegas, 7–9 June 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604645983/en/ Initial use cases span healthcare, financial services, insurance, government, and BPO. The companies will demonstrate a healthcare appointment booking call at PegaWorld, but the same architecture applies to any regulated environment where AI interactions must be executed within governed workflows, using real-time customer context, policy, and decisionin
Mobix Labs to Acquire U.S.-Built Drone Manufacturer Vision Aerial, Expanding Into Global Drone and Aerial Intelligence Markets4.6.2026 14:00:00 CEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a binding Letter of Intent to acquire Vision Aerial, Inc., a Montana-based manufacturer of American-built drones trusted in national security, government, energy, public safety, and critical infrastructure operations. The acquisition expands Mobix Labs into a fast-growing global market and marks the latest step in its previously announced strategy to grow through targeted, mission-critical acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604386607/en/ Built in America. Trusted Where Performance Matters. Founded in 2013, Vision Aerial designs, manufactures, and supports rugged drone systems built for the most demanding field operations. Each aircraft can carry swappable cameras and sensors—from high-resolution and heat-sensing thermal cameras to laser-based 3-D mapping and gas-leak detection—allowing one platform to support multiple mission prof
Visa and Brale Explore Private Stablecoin Settlement for Institutional Payments4.6.2026 14:00:00 CEST | Press release
Proof of concept will test how privacy-enabled blockchain infrastructure can support secure, scalable settlement for institutional payment flows Visa (NYSE: V) today announced a collaboration with Brale to explore stablecoin-based settlement using SBC, a U.S. dollar-backed stablecoin issued by Brale, on the Canton Network. The proof of concept will evaluate how privacy-enabled blockchain infrastructure can support faster, more programmable settlement while helping financial institutions and payment companies maintain control over the visibility of sensitive settlement transaction data. Visa began enabling stablecoin settlement in 2021 and continues to expand its capabilities, allowing VisaNet obligations to be settled using supported stablecoins. A central focus of this collaboration is the Canton Network’s privacy architecture. As stablecoin adoption grows, financial institutions are assessing how they can use blockchain-based settlement while meeting strict privacy and compliance req
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom